<tr id="tp1vn"><td id="tp1vn"><dl id="tp1vn"></dl></td></tr>
  1. <p id="tp1vn"></p>
  2. <sub id="tp1vn"><p id="tp1vn"></p></sub>
    <u id="tp1vn"><rp id="tp1vn"></rp></u>
    <meter id="tp1vn"></meter>
      <wbr id="tp1vn"><sup id="tp1vn"></sup></wbr>
      日韩第一页浮力,欧美a在线,中文字幕无码乱码人妻系列蜜桃 ,国产成人精品三级麻豆,国产男女爽爽爽免费视频,中文字幕国产精品av,两个人日本www免费版,国产v精品成人免费视频71pao
      網易首頁 > 網易號 > 正文 申請入駐

      “以光為刃”,當傳統工藝無解,藥明康德如何將新藥化學合成的鴻溝化為坦途?

      0
      分享至

      在新藥研發道路上,有時候決定成敗的往往不是宏大的敘事,而是一次關鍵化學中間體的高效合成。這類中間體如同精密的齒輪,其結構的細微偏差,都可能導致后續進程的停滯。在藥明康德的眾多客戶里,許多重要合作常常始于一個看似微小卻至關重要的化學工藝節點。

      故事要從一個棘手的分子骨架說起。

      某公司在推進一個極具潛力的分子項目時,被一個關鍵的“路障”卡住了。項目急需構建一個復雜而精確的三維分子骨架。這個骨架,是整個藥物分子的“心臟”,它的形狀、空間結構都必須分毫不差。因此,只有成功構建出正確立體構型的核心骨架,才能構建出具有生物活性的復雜分子,進而有望推進臨床,拯救生命。

      然而,擺在他們面前的,是行業內傳統分批工藝的“瓶頸”。

      傳統分批工藝生產模式是將所有原料按順序投入反應容器中,在設定好的溫度、壓力下攪拌、反應。待反應結束,再進行分離提純,得到產物。在這個項目中,如果采用傳統合成路線,需經過5步反應,效率較低。而且,最終得到的產物里,只有一半是符合要求的立體構型,整體收率也不高。

      更為棘手的是,傳統分批工藝從實驗室的克級探索放大到千克級生產時,橫亙著一條難以逾越的“鴻溝”。這不是簡單地把原料配方乘以1000就能解決的。規模放大后,反應體系的物理環境會發生變化,許多在燒瓶中運行良好的反應,一旦進入大釜,就可能面臨效率下降、甚至失敗風險。要解決這些挑戰,就需要耗費更多時間和資源來重新摸索工藝條件。

      面對難題,該公司第一時間聯系上藥明康德研發化學服務部(Research Chemistry Services,RCS)。這種信任并非憑空而來。它是十多年間,在多個合作項目里,由藥明康德一次次專業、高效的服務交付,一點一滴積累起來的。

      接到任務后,藥明康德RCS團隊迅速組建了由多個研發和生產基地專家構成的項目團隊,一場與時間賽跑的技術攻堅就此拉開序幕。

      如何破解分批工藝收率低、順反選擇性差,以及難以放大的“死結”?團隊的目光投向了光化學工藝技術。


      所謂光化學工藝,是利用特定波長的光能作為“精確的刻刀”,代替傳統的熱能或化學試劑,來精準切斷或重組化學鍵,從而高效構建目標分子。這聽起來似乎有些深奧,但光化學離我們的生活并不遙遠,就像晾在陽臺的彩色衣物,時間久了會慢慢褪色,其實是染料分子在太陽光的照射下發生了光化學反應;或是老式膠片相機按下快門的瞬間,膠片上的感光材料會因吸收光線而發生化學變化,最終定格下影像,也是光化學的典型應用。然而,當光化學技術應用于工業場景時,對設備、對人員的專業素養要求極高,它需要光能均勻、穩定地穿透反應體系,這在傳統的反應釜中幾乎無法實現。

      為此,項目團隊引入了一套高效的技術“組合拳”。

      首先登場的是高通量實驗(HTE),如果說分批工藝是在黑暗中一把把地嘗試“鑰匙”,那HTE就像同時啟動了上百個微型“智能鑰匙”,它能在極短時間內并行測試數百種反應條件——換一種光波長、試一種新催化劑、調一下濃度——過去需要幾周甚至幾個月的摸索,現在可將項目初期的摸索時間壓縮到以天計,從而迅速鎖定關鍵“配方”。

      但僅找到“配方”還不夠,關鍵是如何讓它穩定、高效地運轉起來,并適用于規模放大。于是,流動化學技術便登場亮相。

      想象一下,不再讓原料悶在反應容器里“不均勻光照”,而是將它們像輸液一樣,通過細細的管道持續泵入一個盤成線圈的透明“光隧道”。反應物一邊勻速流動,一邊接受管道外壁均勻的光照,真正實現了“邊走邊反應”。

      在這條精心設計的“光隧道”上,光照條件均勻穩定,反應路徑精準可控。原本需要5步、多批次投放、多次分離、轉移的復雜過程,如今像一條流水線,僅需1步連貫完成。

      結果是令人驚喜的——產物收率良好,順式選擇性極高。更難得的是,項目團隊僅用了9個小時,就完成了100克以上規模的精準制備,這意味著該工藝路線已成功跨越實驗室研究階段,具備了直接為后續毒理研究、臨床試驗提供足量藥物的能力,也為未來更大規模化生產奠定了堅實的技術基礎。這種效率與質量的雙重提升,使得原本預估需要4個多月的項目工期,被大幅縮短至僅10周。

      當項目團隊將高質量的產物交付到客戶手中時,客戶的項目負責人難掩興奮,高度贊賞道:“你們對光化學工藝的掌握和應用令人印象深刻,新的技術為我們打開了路線優化的大門,不僅提高了產量,也讓規模放大成為可能。”

      如今,這家客戶仍有多個后續項目與藥明康德持續合作。


      圖片來源:123RF

      這不僅是藥明康德光化學平臺一次高質量的服務交付,更是公司“讓天下沒有難做的藥,難治的病”這一愿景在微觀層面的生動注腳。這一成功的賦能案例,不僅彰顯了藥明康德在光化學領域的技術深度,更是公司全面化學能力的堅實印證,是公司CRDMO全球賦能平臺在創新浪潮中的一個典型縮影。

      回首二十余載,藥明康德構建的一體化、端到端CRDMO賦能平臺,早已超越了單純的技術疊加。公司將光化學、電化學、流動化學、酶催化等一系列創新技術融會貫通,以更好地賦能全球合作伙伴。因為,每一次分子的合成,背后都是滿懷期待的科學家和客戶,以及等待救治的患者。正是這份敬畏與擔當,驅動公司支持全球數千家合作伙伴破解研發挑戰,加速新藥從分子走向臨床的過程,讓創新療法突破瓶頸,推動更多新藥、好藥早日問世。

      Light and Flow: How WuXi AppTec Bridges the Gap in Novel Drug Chemical Synthesis

      In the journey of new drug development, success or failure often hinges on the efficient synthesis of a single, critical chemical intermediate—far more than on grand narratives. Among WuXi AppTec’s many customers, numerous significant collaborations begin at what may seem like a minor but is in fact a pivotal point in the chemical process.

      The story starts with a challenging molecular scaffold.

      A company was advancing a highly promising molecule when it hit a critical roadblock. The project urgently required the construction of a complex and precise three-dimensional molecular scaffold. This scaffold was the “heart” of the drug molecule; its shape and spatial structure had to be flawless. Therefore, successfully constructing this core scaffold with correct stereo configuration was the only way to build a biologically active complex molecule, ultimately advancing it toward clinical trials and the potential to save lives.

      However, the team faced a bottleneck inherent to traditional batch processing.

      In traditional batch processing, all raw materials are sequentially added to a reaction vessel, stirred, and reacted under set temperature and pressure conditions. Once the reaction is complete, the product is isolated and purified.For this project, the conventional synthetic route would have required five reaction steps, resulting in low efficiency. Moreover, only about half of the final product possessed the required stereo configuration, and the overall yield was low.

      An even greater challenge was the significant gap between gram-scale laboratory exploration and kilogram-scale production using traditional batch methods. This scaling-up process is not a simple matter of multiplying the recipe by a factor of 1000. When a process is scaled up, the physical environment of the reaction system changes. Many reactions that work smoothly in a flask may face decreased efficiency or even fail when transferred to a large reactor. Overcoming these challenges would require substantial additional time and resources to re-optimize the process conditions.

      Faced with this challenge, the company immediately contacted WuXi AppTec’s Research Chemistry Services (RCS) team. This trust was not built overnight. It has been accumulated over more than a decade through multiple collaborative projects, earned through consistent delivery of professional and efficient services.

      Upon receiving the task, the RCS team quickly pulled together experts from multiple sites—kicking off a race against time to tackle the technical challenge.

      How could they solve the intertwined problems of low yield, poor cis-trans selectivity, and the difficulty of scaling up the batch process? The team’s focus turned to photochemistry.


      Photochemistry uses light energy of a specific wavelength as a “precision chisel,” replacing traditional thermal energy or chemical reagents to precisely break or reform chemical bonds, efficiently constructing the target molecule.While this might sound complex, photochemistry is not far from our daily lives. For example, colored clothes left to dry on a balcony slowly fade over time because the dye molecules undergo photochemical reactions under sunlight. Similarly, when a vintage film camera shutter clicks, the photosensitive material on the film absorbs light and undergoes a chemical change, capturing the image—a classic application of photochemistry. However, applying photochemistry in an industrial setting demands highly specialized equipment and expertise. It requires the light energy to penetrate the reaction system uniformly and stably, a feat nearly impossible in traditional reaction vessels.

      To address this, the project team implemented a powerful combination of technologies.

      The first was High-Throughput Experimentation (HTE). If batch processing is like trying keys one by one in the dark, HTE is like activating hundreds of miniature “smart keys” simultaneously. It allows hundreds of reaction conditions—varying the light wavelength, trying a new catalyst, adjusting the concentration—to be tested in parallel within a very short time. What used to take weeks or even months of exploration could now be compressed into days, enabling the team to rapidly lock in a critical “formula.”

      But finding the formula was only half the battle. The key was to make it run stably, efficiently, and in a scalable manner. This is where flow chemistry came into play.

      Imagine, instead of having the raw materials confined in a reactor with uneven light exposure, they were continuously pumped like an intravenous drip through a narrow tube coiled into a transparent “light tunnel.” As the reactants flowed at a constant rate, they received uniform illumination from the outside of the tube wall, truly achieving “reaction on the go.”

      Within this precisely engineered “light tunnel,” the light exposure was consistent and stable, and the reaction pathway was precisely controlled.The original complex process requiring five steps, multiple batch additions, and multiple separations and transfers was streamlined like an assembly line, completed in continuous flow in one step.

      The results were remarkable: excellent product yield, exceptionally high cis-selectivity, andprecise preparation of over 100 grams in just nine hours. This demonstrated that the process had successfully crossed the laboratory research stage, enabling the possibility to directly supply sufficient quantity of the drug candidate for subsequent toxicology studies and clinical trials, and laying a solid technical foundation for future large-scale production.This dual improvement in efficiency and quality shortened the project timeline significantly, from an estimated over four months to just ten weeks.

      When the project team delivered the high-quality product to the client, the client’s project lead couldn’t hide their excitement. "The photochemical process had opened the door to route optimization for us, not only increasing yield but also making it possible to scale-up."

      Since then, this client has continued to collaborate with WuXi AppTec on multiple subsequent projects.


      Image source: 123RF

      This case represents more than just a high-quality service delivery by WuXi AppTec’s photochemistry platform; it is a tangible microcosm of the company’s vision: “Every drug can be made, and every disease can be treated.” This successful enabling story not only highlights WuXi AppTec’s technical depth in the field of photochemistry but also stands as a solid testament to its comprehensive chemistry capabilities, serving as a quintessential example of its global CRDMO enabling platform in action amidst a wave of innovation.

      Looking back over more than two decades, WuXi AppTec’s integrated, end-to-end CRDMO enabling platform has gone beyond a mere collection of technologies. The company has integrated and mastered a suite of innovative technologies—including photochemistry, electrochemistry, flow chemistry, enzymatic catalysis, and beyond—to better enable its global partners. Behind every synthesis of a molecule, what we see are scientists and clients full of anticipation, as well as patients waiting for treatment. It is this sense of respect and responsibility that drives the company to support thousands of customers worldwide in tackling R&D challenges, accelerating the journey of new drugs from molecule to clinical, breaking through bottlenecks in innovative therapies, and helping bring more new and better medicines to patients faster.

      免責聲明:本文僅作信息交流之目的,文中觀點不代表藥明康德立場,亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導,請前往正規醫院就診。

      版權說明:歡迎個人轉發至朋友圈,謝絕媒體或機構未經授權以任何形式轉載至其他平臺。轉載授權請在「藥明康德」微信公眾號回復“轉載”,獲取轉載須知。

      特別聲明:以上內容(如有圖片或視頻亦包括在內)為自媒體平臺“網易號”用戶上傳并發布,本平臺僅提供信息存儲服務。

      Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.

      相關推薦
      熱點推薦
      中國海油:公司國內原油銷售價格參考布倫特現貨油價

      中國海油:公司國內原油銷售價格參考布倫特現貨油價

      每日經濟新聞
      2026-05-15 15:41:07
      985高校兩所醫學院,正式合并!

      985高校兩所醫學院,正式合并!

      醫學界
      2026-05-15 18:56:00
      我跟女總裁說:你要是我媳婦我一天揍你3頓,隔天她帶5個保鏢堵我

      我跟女總裁說:你要是我媳婦我一天揍你3頓,隔天她帶5個保鏢堵我

      千秋文化
      2026-05-13 19:47:04
      中美峰會到底怎么談的臺灣問題?我國外長正式回應

      中美峰會到底怎么談的臺灣問題?我國外長正式回應

      阿龍聊軍事
      2026-05-16 09:34:41
      注意!日本機場狂查,大姐8個箱子被海關扒穿,當場罰到沉默!

      注意!日本機場狂查,大姐8個箱子被海關扒穿,當場罰到沉默!

      東京在線
      2026-05-15 16:30:30
      來中國一趟,讓特朗普觸動很深,回程專機上下令建美版天壇公園?

      來中國一趟,讓特朗普觸動很深,回程專機上下令建美版天壇公園?

      生活魔術專家
      2026-05-15 19:16:18
      里程碑之戰哈登23+7+4+8失誤,米切爾18分比肩詹歐,騎士主場首敗

      里程碑之戰哈登23+7+4+8失誤,米切爾18分比肩詹歐,騎士主場首敗

      釘釘陌上花開
      2026-05-16 09:43:46
      洶涌的資金,正在加速沖進股市

      洶涌的資金,正在加速沖進股市

      睿知睿見
      2026-05-16 07:31:46
      特朗普,買入英偉達、蘋果、英特爾

      特朗普,買入英偉達、蘋果、英特爾

      智東西
      2026-05-16 09:27:14
      怪不得劉律建議毛巾少爺去二叔化,原來周揚青早點破他被家族綁定

      怪不得劉律建議毛巾少爺去二叔化,原來周揚青早點破他被家族綁定

      一盅情懷
      2026-05-15 17:10:38
      導游恩施大峽谷帶團時書包斷裂,背簍嬢嬢掏出針線縫好,視頻獲超3萬點贊,景區:正推進獎勵

      導游恩施大峽谷帶團時書包斷裂,背簍嬢嬢掏出針線縫好,視頻獲超3萬點贊,景區:正推進獎勵

      揚子晚報
      2026-05-15 20:17:45
      面臨淘汰露死亡之瞳!CC21+8連續兩輪入搶七 活塞6人上雙打臉美記

      面臨淘汰露死亡之瞳!CC21+8連續兩輪入搶七 活塞6人上雙打臉美記

      顏小白的籃球夢
      2026-05-16 09:56:29
      確實沒讓步!中國回應中美峰會談臺島,魯比奧稱政策不變

      確實沒讓步!中國回應中美峰會談臺島,魯比奧稱政策不變

      阿龍聊軍事
      2026-05-16 09:29:55
      斯諾克:墨菲爆冷一輪游,5-4,四強火箭VS囧哥

      斯諾克:墨菲爆冷一輪游,5-4,四強火箭VS囧哥

      吳朑愛游泳
      2026-05-16 07:13:12
      孫儷教子有方!女兒英國比賽獲獎身披國旗上臺,自信大方像鄧超

      孫儷教子有方!女兒英國比賽獲獎身披國旗上臺,自信大方像鄧超

      白面書誏
      2026-05-15 13:56:08
      守田英正自宣離開葡體:我永遠不會為葡萄牙的其他俱樂部效力

      守田英正自宣離開葡體:我永遠不會為葡萄牙的其他俱樂部效力

      懂球帝
      2026-05-16 01:54:03
      來了來了!19歲超級新星!正式打進中國男籃

      來了來了!19歲超級新星!正式打進中國男籃

      籃球實戰寶典
      2026-05-15 17:19:02
      樊振東被棄用不到24小時,正式官宣“新身份”,終于等到這一天

      樊振東被棄用不到24小時,正式官宣“新身份”,終于等到這一天

      做一個合格的吃瓜群眾
      2026-05-15 14:45:15
      編外人員“清退”開始,城管協管、輔警、護士教師都在其中

      編外人員“清退”開始,城管協管、輔警、護士教師都在其中

      巢客HOME
      2026-05-14 05:55:06
      奇瑞董事長尹同躍:已為智界投入200多億專項資金,智界V9累計小訂突破4萬輛

      奇瑞董事長尹同躍:已為智界投入200多億專項資金,智界V9累計小訂突破4萬輛

      新浪財經
      2026-05-15 15:21:10
      2026-05-16 10:20:49
      醫藥觀瀾
      醫藥觀瀾
      中國及全球新藥觀察
      5589文章數 13467關注度
      往期回顧 全部

      科技要聞

      直降千元起步!蘋果華為率先開啟618讓利

      頭條要聞

      特朗普抵京當晚在機場執勤的禮兵震動外網 詳情披露

      頭條要聞

      特朗普抵京當晚在機場執勤的禮兵震動外網 詳情披露

      體育要聞

      35歲坎特,干了一件這輩子最吵的事

      娛樂要聞

      張嘉譯和老婆的差距讓人心酸

      財經要聞

      造詞狂魔賈躍亭

      汽車要聞

      高爾夫GTI刷新紐北紀錄 ID. Polo GTI迎全球首秀

      態度原創

      家居
      旅游
      游戲
      本地
      軍事航空

      家居要聞

      110㎡淡而有致的生活表達

      旅游要聞

      首屆中國新文創市集暨潮玩游園會在京開幕

      全魔獸最團結的教派,專注搞事20年,首領居然是個食人魔?

      本地新聞

      用蘇繡的方式,打開江西婺源

      軍事要聞

      聯合國安理會審議敘利亞局勢

      無障礙瀏覽 進入關懷版 主站蜘蛛池模板: 日韩视频一区二区中文经典| 午夜精品福利亚洲国产| metart亚洲裸体中国| 国产人妻精品一区二区三区不卡 | 国产精品无码av不卡| 少妇高潮毛片免费看| 丁香六月天| 亚洲一区二区三区成人网站| 精品麻豆剧传媒av国产| 免费观看日本污污ww网站 | 免费无码高潮流白浆视频| 亚洲精品97久久一| 天天综合一区| 色婷婷综合久色aⅴ五区最新| 国产AV影片麻豆精品传媒| 亚洲精品日韩av| 亚洲av无码专区国产乱码电影| 国产精品天干在线观看| 欧美成人精品三级在线观看| 中文字幕人妻系列| 欧美亚洲中文| 国产成人精品无码片区在线观看| 国产免费一区二区三区在线观看| 国产欧美另类精品久久久| 尤物av无码色av无码| 国产免费一级高清淫日本片| av毛片无码中文字幕不卡| 亚洲精品午夜无码专区| 亚洲精品日韩在线观看| 久久精品只有这里有| 202丰满熟女妇大| 婷婷五月综合丁香在线| av二区三区| 男女做aj视频免费的网站| 亚洲av成人免费在线| 中文字幕无码人妻aaa片| 成人性生交片无码免费看| 午夜日韩| 亚洲最大成人av在线| 激情偷乱人伦小说视频| 日本道精品一区二区三区|